Genentech, Inc., South San Francisco, CA
Mary K. Downer , Amin Yakubu , Pablo Diego Pérez-Moreno , Anna Steenrod , Tanja Badovinac Crnjevic , Zuzana Machackova
Background: Despite high endocrine therapy (ET) efficacy in HR+ EBC, there is an unmet need to improve outcomes across risk statuses. We describe HR+ EBC demographic and tumor characteristics, treatment, and outcomes by risk status, to inform trial design, outcomes, and care. Methods: Pts from the de-identified, nationwide US, Flatiron Health electronic health record-derived database had HR+ EBC diagnosed from January 1, 2011 to November 30, 2020. We grouped pts into EBC with clinically relevant, high risk (stage T4 or ≥N2; or N1 with ≥1 of ≥T3, grade 3, Ki67 ≥20%, Oncotype DX ≥26), medium risk (N1, not high risk; or N0 with ≥1 of grade 3, Ki67 ≥20%, Oncotype DX ≥26), or low risk (N0, not medium risk) of recurrence. Chi-square and Kruskal–Wallis tests compared characteristics and treatments; Kaplan–Meier methods estimated event-free/overall survival (EFS/OS). Results: Of 7924 pts, 3908 (49.3%), 2477 (31.3%), and 1213 (15.3%) were classified as low-, medium-, and high-risk EBC, respectively (326 missing). Pts with medium-/high-risk EBC vs low-risk were less likely to be non-Hispanic white (p < 0.001), more likely to receive BRCA, MammaPrint, or next-generation sequencing testing (p < 0.001), be slightly younger (p < 0.001), pre-menopausal at diagnosis (p < 0.001), diagnosed in earlier calendar years (p = 0.01), and have invasive lobular carcinoma (p < 0.001). Pts with high-risk EBC were more likely to receive neoadjuvant chemotherapy (NACT) ± ACT vs lower risk. High-risk EBC had significantly lower 3-year EFS/OS vs medium-/low-risk (EFS 0.85 [95% CI = 0.82, 0.87] vs 0.95 [0.94, 0.96]/0.98 [0.98, 0.99], p < 0.0001; OS 0.9 [0.88, 0.92] vs 0.97 [0.96, 0.97]/0.97 [0.96, 0.97], p < 0.0001). Conclusions: Real-world differences in US characteristics, treatments, and outcomes by risk status exist in HR+ EBC. As expected, pts with higher risk EBC were more likely to receive NACT ± ACT. Despite missing risk factors and limited follow-up, and potential misclassification of risk status/treatment and overestimation of time-to-events, US treatment patterns are guideline-aligned. Inferior outcomes in high-risk HR+ EBC show a continued need for improved treatments.
Risk | |||
---|---|---|---|
Characteristic at diagnosis | Low (n = 3908) | Medium (n = 2477) | High (n = 1213) |
Age, median (interquartile range) | 65 (56–73) | 62 (53–71) | 61 (50–70) |
Non-Hispanic White | 2658 (68.0) | 1598 (64.5) | 737 (60.8) |
Pre-menopausal | 571 (14.6) | 447 (18.0) | 283 (23.3) |
Testing BRCA MammaPrint NGS | 1027 (26.3) 157 (4.0) 27 (0.7) | 785 (31.7) 163 (6.6) 61 (2.5) | 439 (36.2) 65 (5.4) 94 (7.7) |
NACT ± ACT | 44 (1.1) | 170 (6.9) | 186 (15.3) |
ACT only | 182 (4.7) | 704 (28.4) | 493 (40.6) |
Adjuvant ET only1 | 2856 (73.1) | 1203 (48.6) | 308 (25.4) |
Data: n (%) unless specified. 1Other/missing: 826 (21.1), 400 (16.1), 228 (18.6); predominantly pts with evidence of surgery only (i.e. no systemic therapy) – many were likely lost to follow-up prior to systemic therapy and/or received therapy outside of Flatiron Health.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Tarek Mohamed Ahmed Abdel-Fatah
2024 ASCO Genitourinary Cancers Symposium
First Author: Siqi Hu
2021 ASCO Annual Meeting
First Author: Hans-Christian Kolberg
2024 ASCO Annual Meeting
First Author: Shingo Hatakeyama